Evaluation of Cardiac Function in Patients with Brain Death using Advanced Hemodynamic Monitoring
author
Abstract:
Background: Studies on hemodynamic changes in brain death are in vitro and in animal studies. And very few studies have been done on the hemodynamic changes of brain death. The aim of this study was to use advanced hemodynamic monitoring with echocardiography for evaluation of donated heart and to evaluate the moment by moment brain death patients with advanced hemodynamic monitoring tools and its effect on organ donation outcome. Methods: This cross-sectional analytical study was performed on the patients with brain death who were candidates for organ donation in Dr. Masih Daneshvari Hospital between 2017 and 2019. Forty-two patients with brain death who were candidate for heart donation were evaluated using purposive sampling. After echocardiography and initial evaluation, these patients were evaluated using advanced hemodynamic monitoring tools and the required data were collected and recorded. Results: In echocardiography, Left Ventricle Size (LVS) was normal in 100% of patients and Left Ventricle Function (LVF) in 87.5%. Left Ventricle Ejection Fraction (LVEF) was less than 50% in 12.5% and in 87.5% it was more than 50%. In 50% of patients at baseline, peripheral vascular resistance (Systemic Vascular Resistance-SVR) was lower than 1200 and at the end of study it raised to 54.4%. Cardiac Index (CI) was lower than 2.4 in 16.7% of patients at baseline and 25% at the end of study. Decreased CI and decreased vascular resistance in patients with Ejection Fraction (EF) less than 50% were also significantly higher than in patients with EF above 50%. Conclusion: Due to the extensive pathological changes that brain death has on the cardiovascular system, advanced hemodynamic monitoring can continuously manage inotropic drugs in these patients, decide to manage intravascular volume and ultimately stabilize hemodynamic and prevent destruction.
similar resources
Evaluation of Cardiac Function in Patients with Thalassemia Intermedia
Abstract Background Thalassemia intermedia is a variety of beta thalassemia which shows clinical symptoms somewhere between asymptomatic carriers and thalassemia major. Cardiac dysfunctions due to chronic anemia and hemosiderosis are the major causes of death in these patients. The purpose of this study is to evaluate cardiac function in these patients by echocardiography. Materials and Met...
full textHemodynamic analysis of brain death patients using pulse-induced contour cardiac output (PiCCO)
The aim of this study is to investigate the hemodynamic characteristics of brain death patients via PulseInduced Contour Cardiac Output (PiCCO). 20 brain-death patients were included in the test group, and 20 with GCS ≥ 8 were included in the control group. The hemodynamic characteristics Pre-load (ITBVI/ EVLWI), Cardiac Pump Function: (CI/SI/GEF/CFI/dPmax), Post-load: (SVRI) were collected by ...
full textComparison of Cardiac Function in Young Patients with Thalassemia Intermedia and Healthy Individuals Using Echocardiography Method
Background: Cardiac dysfunction due to chronic anemia and hemosiderosis are the major causes of death among patients with thalassemia intermedia. This study was performed to compare the cardiac function in thalassemia intermedia patients with normal subjects by means of echocardiography. Materials and Methods: This was a case-control study performed on 22 patients affected by thalassemia int...
full textMetoprolol improves endothelial function in patients with cardiac syndrome X
Endothelial dysfunction which is manifested by the loss of nitric oxide bioavailability, is an increasingly recognized cause of cardiac syndrome X (CSX) and beta blockers are used for the treatment of this syndrome. Thus, the aim of this study was to investigate effects of metoprolol, as a beta blocker, on endothelial function in CSX patients. The study included 25 CSX patients (20 female/ 5 ma...
full textMetoprolol improves endothelial function in patients with cardiac syndrome X
Endothelial dysfunction which is manifested by the loss of nitric oxide bioavailability, is an increasingly recognized cause of cardiac syndrome X (CSX) and beta blockers are used for the treatment of this syndrome. Thus, the aim of this study was to investigate effects of metoprolol, as a beta blocker, on endothelial function in CSX patients. The study included 25 CSX patients (20 female/ 5 ma...
full textMy Resources
Journal title
volume 37 issue 2
pages 94- 101
publication date 2019-10
By following a journal you will be notified via email when a new issue of this journal is published.
No Keywords
Hosted on Doprax cloud platform doprax.com
copyright © 2015-2023